Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 18/20 | 0.68 |
| ▸ | EIF2AK1 | Q9BQI3 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27975489 | 0.91 | EIF2AK3 (0.67) | EIF2AK3EIF2AK1KDRCYP11B1CYP11B2 | |
| SCHEMBL870192 | 0.86 | EIF2AK3 (0.61) | EIF2AK3EIF2AK1KDRCYP11B1CYP11B2 | |
| SCHEMBL2373601 | 0.83 | EIF2AK3 (0.61) | EIF2AK3EIF2AK1KDR | |
| SCHEMBL869562 | 0.81 | EIF2AK3 (1.00) | EIF2AK3EIF2AK1 | |
| SCHEMBL868264 | 0.81 | EIF2AK3 (0.69) | EIF2AK3EIF2AK1LCKAURKB | |
| SCHEMBL868562 | 0.80 | EIF2AK3 (0.72) | EIF2AK3EIF2AK1LCKAURKB | |
| SCHEMBL868852 | 0.80 | EIF2AK3 (0.75) | EIF2AK3EIF2AK1LCKAURKB | |
| SCHEMBL869570 | 0.80 | EIF2AK3 (0.85) | EIF2AK3EIF2AK1 | |
| SCHEMBL868870 | 0.74 | EIF2AK3 (0.67) | EIF2AK3KDRLCKAURKBCYP11B1 | |
| SCHEMBL17749182 | 0.70 | RIPK1 (0.64) | EIF2AK3EIF2AK1KDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885EIF2AK1 20/4885KDR 3297/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885EIF2AK1 20/4885KDR 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.